{"drugs":["Ceftriaxone Sodium","Rocephin"],"mono":{"0":{"id":"111736-s-0","title":"Generic Names","mono":"Ceftriaxone Sodium"},"1":{"id":"111736-s-1","title":"Dosing and Indications","sub":[{"id":"111736-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acute otitis media:<\/b> 1 to 2 g IV\/IM every 24 hours or in divided doses twice a day; MAX 4 g\/day<\/li><li><b>Bacteremia associated with intravascular line:<\/b> Due to Escherichia coli and Klebsiella species, extended-spectrum beta-lactamase negative: 1 to 2 g IV daily (guideline dose)<\/li><li><b>Bacterial endocarditis; Prophylaxis:<\/b> High-risk patients; dental, respiratory, or infected skin\/skin structure, or musculoskeletal tissue procedures: 1 g IV\/IM 30 to 60 minutes prior to procedure (guideline dose)<\/li><li><b>Bacterial meningitis:<\/b> 4 g\/day IV divided every 12 to 24 hours; MAX 4 g\/day (guideline dose)<\/li><li><b>Bacterial musculoskeletal infection:<\/b> 1 to 2 g IV\/IM every 24 hours or in divided doses twice a day; MAX 4 g\/day<\/li><li><b>Chancroid:<\/b> 250 mg IM as a single dose (guideline dose)<\/li><li><b>Epididymitis:<\/b> 250 mg IM as a single dose plus doxycycline 100 mg orally twice daily for 10 days (guideline dose)<\/li><li><b>Gonorrhea:<\/b> Uncomplicated: 250 mg IM as a single dose plus either a single dose of azithromycin 1 g orally or doxycycline 100 mg orally twice daily for 7 days (guideline dose)<\/li><li><b>Gonorrhea:<\/b> Conjunctivitis: 1 g IM as a single dose (guideline dose)<\/li><li><b>Gonorrhea:<\/b> Disseminated: 1 g IV\/IM every 24 hours for 24 to 48 hours; after improvement begins then switch to appropriate oral therapy to complete at least 1 week of therapy (guideline dose)<\/li><li><b>Gonorrhea:<\/b> Meningitis and endocarditis: 1 to 2 g IV every 12 hours, for 10 to 14 days (meningitis) or at least 4 weeks (endocarditis; guideline dose)<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> 1 to 2 g IV\/IM every 24 hours or in divided doses twice a day; MAX 4 g\/day<\/li><li><b>Infectious disease of abdomen:<\/b> 1 to 2 g IV\/IM every 24 hours or in divided doses twice a day; MAX 4 g\/day<\/li><li><b>Infective endocarditis:<\/b> Native valve, highly penicillin-susceptible streptococci: 2 g IV\/IM every 24 hours for 4 weeks<\/li><li><b>Infective endocarditis:<\/b> Native valve, highly penicillin-susceptible streptococci: Alternative therapy, 2 g IV\/IM every 24 hours AND gentamicin sulfate 3 mg\/kg IV\/IM in 1 dose (preferred) or in 3 equally divided doses for 2 weeks<\/li><li><b>Infective endocarditis:<\/b> Native valve, relatively penicillin-resistant streptococci: 2 g IV\/IM every 24 hours for 4 weeks AND gentamicin sulfate 3 mg\/kg IV\/IM in 1 dose (preferred) or in 3 equally divided doses for 2 weeks<\/li><li><b>Infective endocarditis:<\/b> Prosthetic valve, penicillin-susceptible streptococci: 2 g IV\/IM every 24 hours for 6 weeks WITH or WITHOUT gentamicin sulfate 3 mg\/kg IV\/IM in 1 dose (preferred) or in 3 equally divided doses for 2 weeks<\/li><li><b>Infective endocarditis:<\/b> Prosthetic valve, penicillin-resistant streptococci: 2 g IV\/IM every 24 hours AND gentamicin sulfate 3 mg\/kg IV\/IM in 1 dose (preferred) or in 3 equally divided doses for 6 weeks<\/li><li><b>Infective endocarditis:<\/b> Enterococcal, strains resistant to penicillin, aminoglycoside, and vancomycin (E faecalis): 2 g IV\/IM every 12 hours AND ampicillin sodium 2 g IV every 4 hours for a minimum of 8 weeks<\/li><li><b>Infective endocarditis:<\/b> HACEK microorganisms: 2 g IV\/IM every 24 hours for 4 to 6 weeks<\/li><li><b>Infective endocarditis:<\/b> Suspected Bartonella, culture-negative: 2 g IV\/IM every 24 hours for 6 weeks AND gentamicin sulfate 1 mg\/kg IV\/IM every 8 hours for 2 weeks WITH or WITHOUT doxycycline 100 mg IV or ORALLY every 12 hours for 6 weeks<\/li><li><b>Infective proctitis:<\/b> 250 mg IM as a single dose plus doxycycline 100 mg orally twice daily for 7 days (guideline dose)<\/li><li><b>Lower respiratory tract infection:<\/b> 1 to 2 g IV\/IM every 24 hours or in divided doses twice a day; MAX 4 g\/day<\/li><li><b>Lyme disease:<\/b> Early Lyme disease with acute neurological disease manifested by meningitis or radiculopathy, or patients with seventh-cranial-nerve palsy with CNS involvement: 2 g IV once daily for 14 days (range, 10 to 28 days) (guideline dose)<\/li><li><b>Lyme disease:<\/b> Initial treatment of hospitalized patients with Lyme carditis: 2 g IV once daily for 14 to 21 days (guideline dose)<\/li><li><b>Lyme disease:<\/b> Lyme arthritis with neurological involvement, including those refractory to oral therapy, or late neurologic Lyme disease: 2 g IV once daily for 14 to 28 days (guideline dose)<\/li><li><b>Neurosyphilis:<\/b> 2 g daily IV\/IM for 10 to 14 days (guideline dose)<\/li><li><b>Pelvic inflammatory disease:<\/b> 250 mg IM as a single dose plus doxycycline 100 mg orally twice daily for 14 days, with or without metronidazole 500 mg orally twice daily for 14 days (guideline dose)<\/li><li><b>Pelvic inflammatory disease:<\/b> 1 to 2 g IV\/IM every 24 hours or in divided doses twice a day; MAX 4 g\/day (manufacturer dose)<\/li><li><b>Postoperative infection; Prophylaxis:<\/b> 1 g IV 0.5 to 2 hours prior to surgery<\/li><li><b>Septicemia:<\/b> 1 to 2 g IV every 24 hours or in divided doses twice a day; MAX 4 g\/day<\/li><li><b>Sexually transmitted infectious disease; Prophylaxis - Victim of sexual aggression:<\/b> 250 mg IM as a single dose plus metronidazole 2 g orally as a single dose plus either azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days (guideline dose)<\/li><li><b>Urinary tract infectious disease:<\/b> 1 to 2 g IV\/IM every 24 hours or in divided doses twice a day; MAX 4 g\/day<\/li><\/ul>"},{"id":"111736-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Acute otitis media:<\/b> Initial treatment, unable to tolerate oral antibiotics or penicillin allergy: 50 mg\/kg IV\/IM as a single dose, or once daily for 3 days (guideline dosing)<\/li><li><b>Acute otitis media:<\/b> Treatment failure: 50 mg\/kg IV\/IM once daily for 3 days (guideline dosing)<\/li><li><b>Acute otitis media:<\/b> 50 mg\/kg IM as a single dose; MAX 1 g\/dose (manufacturer dosing)<\/li><li><b>Bacterial endocarditis; Prophylaxis:<\/b> High-risk patients; dental, respiratory, or infected skin\/skin structure, or musculoskeletal tissue procedures: 50 mg\/kg IV or IM 30 to 60 minutes prior to procedure (guideline dose)<\/li><li><b>Bacterial meningitis:<\/b> (Older than 28 days) 80 to 100 mg\/kg\/day IV divided every 12 to 24 hours (guideline dose); MAX 4 g\/day<\/li><li><b>Bacterial musculoskeletal infection:<\/b> 50 to 75 mg\/kg\/day IV\/IM in divided doses every 12 hours; MAX 2 g\/day<\/li><li><b>Gonorrhea:<\/b> Uncomplicated (45 kg or less): 125 mg IM as a single dose (guideline dose)<\/li><li><b>Gonorrhea:<\/b> Concomitant bacteremia or arthritis: 50 mg\/kg IM\/IV in a single daily dose for 7 days; MAX 1 g\/dose (guideline dose)<\/li><li><b>Gonorrhea:<\/b> Disseminated and scalp abscesses (newborns): 25 to 50 mg\/kg IV\/IM once daily for 7 days; treat 10 to 14 days for meningitis (guideline dose)<\/li><li><b>Gonorrhea:<\/b> Ophthalmia neonatorum: 25 to 50 mg\/kg IV\/IM as a single dose; MAX 125 mg dose (guideline dose)<\/li><li><b>Gonorrhea:<\/b> Prophylaxis for newborn (maternal gonococcal infection): 25 to 50 mg\/kg IV\/IM as a single dose; MAX 125 mg dose (guideline dose)<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> 50 to 75 mg\/kg\/day IV\/IM once daily or in divided doses every 12 hours; MAX 2 g\/day<\/li><li><b>Infectious disease of abdomen:<\/b> 50 to 75 mg\/kg\/day IV\/IM in divided doses every 12 hours; MAX 2 g\/day<\/li><li><b>Infective endocarditis:<\/b> Native valve, highly penicillin-susceptible streptococci: 100 mg\/kg IV\/IM every 24 hours for 4 weeks; MAX 2 g\/day<\/li><li><b>Infective endocarditis:<\/b> Native valve, highly penicillin-susceptible streptococci: Alternative therapy, 100 mg\/kg IV\/IM every 24 hours (MAX 2 g\/day) AND gentamicin sulfate 3 mg\/kg\/day IV\/IM in 1 dose or 3 equally divided doses for 2 weeks<\/li><li><b>Infective endocarditis:<\/b> Native valve, relatively penicillin-resistant streptococci: 100 mg\/kg IV\/IM every 24 hours for 4 weeks (MAX 2g\/day) AND gentamicin sulfate 3 mg\/kg\/day IV\/IM in 1 dose or 3 equally divided doses for 2 weeks<\/li><li><b>Infective endocarditis:<\/b> Prosthetic valve, penicillin-susceptible streptococci: 100 mg\/kg IV\/IM every 24 hours (MAX 2 g\/day) for 6 weeks WITH or WITHOUT gentamicin sulfate 3 mg\/kg\/day IV\/IM in 1 dose or 3 equally divided doses for 2 weeks<\/li><li><b>Infective endocarditis:<\/b> Prosthetic valve, penicillin-resistant streptococci: 100 mg\/kg IV\/IM every 24 hours (MAX 2 g\/day) AND gentamicin sulfate 3 mg\/kg\/day IV\/IM in 1 dose or 3 equally divided doses for 6 weeks<\/li><li><b>Infective endocarditis:<\/b> Enterococcal, strains resistant to penicillin, aminoglycoside, and vancomycin (E faecalis): 50 mg\/kg IV\/IM every 12 hours (MAX 2 g\/dose) AND ampicillin sodium 300 mg\/kg\/day IV in 4 to 6 equally divided doses (MAX 12 g\/day) for a minimum of 8 weeks<\/li><li><b>Infective endocarditis:<\/b> HACEK microorganisms: 100 mg\/kg IV\/IM every 24 hours (MAX 2 g\/day) for 4 to 6 weeks<\/li><li><b>Infective endocarditis:<\/b> Suspected Bartonella, culture-negative: 100 mg\/kg IV\/IM every 24 hours (MAX 2 g\/day) for 6 weeks AND gentamicin sulfate 1 mg\/kg IV\/IM every 8 hours for 2 weeks WITH or WITHOUT doxycycline 1 to 2 mg\/kg IV or orally every 12 hours (MAX 200 mg\/day) for 6 weeks<\/li><li><b>Lower respiratory tract infection:<\/b> 50 to 75 mg\/kg\/day IV\/IM in divided doses every 12 hours; MAX 2 g\/day<\/li><li><b>Lower respiratory tract infection:<\/b> Community acquired pneumonia (older than 3 months): 50 to 100 mg\/kg\/day IV\/IM in 1 to 2 divided doses every 12 to 24 hours (guideline dosing)<\/li><li><b>Lyme disease:<\/b> Early Lyme disease for acute neurological disease manifested by meningitis or radiculopathy, or patients with seventh-cranial-nerve palsy with CNS involvement: 50 to 75 mg\/kg\/day in a single daily IV dose for 14 days (range, 10 to 28 days); MAX 2 g\/day (guideline dose)<\/li><li><b>Lyme disease:<\/b> Initial treatment of hospitalized patients with Lyme carditis: 50 to 75 mg\/kg\/day in a single IV dose for 14 to 21 days; MAX 2 g\/day (guideline dose)<\/li><li><b>Lyme disease:<\/b> Lyme arthritis with neurological involvement, including those refractory to oral therapy, or late neurologic Lyme disease: 50 to 75 mg\/kg\/day in a single IV dose for 14 to 28 days; MAX 2 g\/day (guideline dose)<\/li><li><b>Septicemia:<\/b> 50 to 75 mg\/kg\/day IV in divided doses every 12 hours; MAX 2 g\/day<\/li><li><b>Typhoid fever:<\/b> 50 to 80 mg\/kg\/day IM, usually given once a day (study dose) (Frenck et al, 2004: Frenck et al, 1999<\/li><li><b>Urinary tract infectious disease:<\/b> 50 to 75 mg\/kg\/day IV\/IM in divided doses every 12 hours; MAX 2 g\/day<\/li><\/ul>"},{"id":"111736-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no dose adjustment needed<\/li><li><b>hepatic impairment:<\/b> no dose adjustment needed<\/li><li><b>combined renal and hepatic impairment:<\/b> doses should not exceed 2 g\/day<\/li><\/ul>"},{"id":"111736-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acute otitis media<\/li><li>Bacterial meningitis<\/li><li>Bacterial musculoskeletal infection<\/li><li>Gonorrhea<\/li><li>Infection of skin AND\/OR subcutaneous tissue<\/li><li>Infectious disease of abdomen<\/li><li>Lower respiratory tract infection<\/li><li>Pelvic inflammatory disease<\/li><li>Postoperative infection; Prophylaxis<\/li><li>Septicemia<\/li><li>Urinary tract infectious disease<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Bacteremia associated with intravascular line<\/li><li>Bacterial endocarditis; Prophylaxis<\/li><li>Bacterial endocarditis - Streptococcal infectious disease<\/li><li>Chancroid<\/li><li>Epididymitis<\/li><li>Febrile neutropenia<\/li><li>Infective endocarditis<\/li><li>Infective proctitis<\/li><li>Lyme disease<\/li><li>Neurosyphilis<\/li><li>Peritonitis<\/li><li>Salmonella infection<\/li><li>Sexually transmitted infectious disease; Prophylaxis - Victim of sexual aggression<\/li><li>Typhoid fever<\/li><li>Upper respiratory infection<\/li><\/ul>"}]},"3":{"id":"111736-s-3","title":"Contraindications\/Warnings","sub":[{"id":"111736-s-3-9","title":"Contraindications","mono":"<ul><li>concurrent administration of calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition, in neonates aged 28 days or less due to risk of fatal salt precipitation in lungs and kidneys<\/li><li>hyperbilirubinemic neonates, due to increased risk of bilirubin encephalopathy (kernicterus), especially in premature neonates<\/li><li>hypersensitivity to cephalosporins<\/li><\/ul>"},{"id":"111736-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- history of gastrointestinal disease, particularly colitis<\/li><li>-- biliary stasis and biliary sludge risk factors, such as preceding major therapy, severe illness, and total parenteral nutrition; increased risk of pancreatitis, possibly secondary to biliary obstruction<\/li><li>-- sonographic abnormalities in gallbladder may occur due to ceftriaxone-calcium salt precipitate, which may be misinterpreted as gallstones<\/li><li>Hematologic:<\/li><li>-- hemolytic anemia, including fatal cases, has been reported; discontinue if condition occurs<\/li><li>-- caution in patients with impaired vitamin K synthesis or low vitamin K stores due to risk of rare prothrombin time alteration<\/li><li>Hepatic:<\/li><li>-- hepatic dysfunction with significant renal disease increases risk of drug toxicity<\/li><li>Immunologic:<\/li><li>-- caution in patients with history of allergy, particularly to any drug, due to increased risk of acute hypersensitivity reaction<\/li><li>-- hypersensitivity to penicillins<\/li><li>Renal:<\/li><li>-- renal failure; increased risk of drug toxicity<\/li><li>Other:<\/li><li>-- do not concurrently administer calcium-containing IV solutions in same IV line, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site; may be administered sequentially in patients other than neonates with thorough flushing of lines with compatible fluid between administrations<\/li><li>-- prolonged treatment may result in superinfection due to overgrowth of nonsusceptible organisms<\/li><li>-- malnutrition increases risk of altered prothrombin time due to low vitamin K stores<\/li><\/ul>"},{"id":"111736-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Ceftriaxone: B (FDA)<\/li><li>Ceftriaxone: B1 (AUS)<\/li><\/ul>"},{"id":"111736-s-3-12","title":"Breast Feeding","mono":"<ul><li>Ceftriaxone: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Ceftriaxone: WHO: Compatible with breastfeeding.<\/li><li>Ceftriaxone: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"111736-s-4","title":"Drug Interactions","sub":{"0":{"id":"111736-s-4-13","title":"Contraindicated","mono":"<ul><li>Calcium Acetate (probable)<\/li><li>Calcium Chloride (probable)<\/li><li>Calcium Gluceptate (probable)<\/li><li>Calcium Gluconate (probable)<\/li><li>Lactated Ringer's Solution (probable)<\/li><li>Ringer's Solution (probable)<\/li><\/ul>"},"2":{"id":"111736-s-4-15","title":"Moderate","mono":"<ul>Warfarin (probable)<\/ul>"}}},"5":{"id":"111736-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Induration at injection site, Warmth, tightness, or induration (5% to 17%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (2.7% to 5.6%)<\/li><li><b>Hematologic:<\/b>Eosinophilia (6%), Thrombocytosis (5.1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Pseudomembranous enterocolitis<\/li><li><b>Hematologic:<\/b>Hemolytic anemia (less than 1%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (2.7% to 3.3%)<\/li><li><b>Neurologic:<\/b>Kernicterus of newborn<\/li><li><b>Renal:<\/b>Renal failure<\/li><li><b>Respiratory:<\/b>Injury of lung<\/li><\/ul>"},"6":{"id":"111736-s-6","title":"Drug Name Info","sub":{"0":{"id":"111736-s-6-17","title":"US Trade Names","mono":"Rocephin<br\/>"},"2":{"id":"111736-s-6-19","title":"Class","mono":"<ul><li>3rd Generation Cephalosporin<\/li><li>Antibiotic<\/li><\/ul>"},"3":{"id":"111736-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"111736-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"111736-s-7","title":"Mechanism Of Action","mono":"Ceftriaxone, a broad-spectrum cephalosporin, exhibits bactericidal activity by the inhibition of bacterial wall synthesis. In the presence of beta-lactamase bacteria, including penicillinases and cephalosporinases, ceftriaxone maintains a high degree of stability.<br\/>"},"8":{"id":"111736-s-8","title":"Pharmacokinetics","sub":[{"id":"111736-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, IV: end of infusion (30 minutes); IM: 1 to 3 hours<\/li><li>Bioavailability, IM 100%<\/li><\/ul>"},{"id":"111736-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 85% (300 mcg\/mL) to 95% (less than 25 mcg\/mL), reversibly bound<\/li><li>Vd: 5.78 to 13.5 L; 338 to 373 mL\/kg<\/li><\/ul>"},{"id":"111736-s-8-25","title":"Metabolism","mono":"minimally metabolized <br\/>"},{"id":"111736-s-8-26","title":"Excretion","mono":"<ul><li>Fecal via bile: remaining amount after renal excretion as inactive compounds<\/li><li>Renal: 33% to 67% unchanged<\/li><li>Dialyzable: No<\/li><li>Total body clearance: adult, 0.58 to 1.45 L\/hr; pediatric, 49 to 60 mL\/hr\/kg<\/li><\/ul>"},{"id":"111736-s-8-27","title":"Elimination Half Life","mono":"<ul><li>5.8 to 8.7 hours<\/li><li>4 to 6.5 hours, neonates and children; 19 hours, infants 1 to 8 days old weighing 1.78 to 4.36 kg<\/li><li>Hemodialysis (CrCl 0 to 5 mL\/min), 14.7 hours; Severe (CrCl 5 to 15 mL\/min), 15.7 hours; Moderate (CrCl 16 to 30 mL\/min), 11.4 hours; Mild (CrCl 31 to 60 mL\/min), 12.4 hours<\/li><\/ul>"}]},"9":{"id":"111736-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>do not reconstitute vials or administer simultaneously with calcium-containing solutions (eg, Ringer or Hartmann solution), products, or continuous calcium-containing solutions (eg, parenteral nutrition) in the same IV line or Y-site due to risk of precipitate formation<\/li><li>reconstitute with appropriate type and amount of diluent and shake thoroughly<\/li><\/ul><\/li><li><b>Intramuscular<\/b><br\/><ul><li>Appropriate diluents are sterile water for injection, NS, D5W, bacteriostatic water (with 0.9% benzyl alcohol), and 1% lidocaine solution (without epinephrine).<\/li><li>Reconstitution of the 250-mg and 500-mg vials with 0.9 mL and 1.8 mL, respectively, of appropriate diluent results in a concentration of 250 mg\/mL; reconstitution of the 500-mg vial with 1 mL of diluent results in a concentration of 350 mg\/mL.<\/li><li>Reconstitution of the 1-g and 2-g vials with 3.6 mL and 7.2 mL, respectively, of appropriate diluent results in a concentration of 250 mg\/mL; reconstitution with 2.1 mL and 4.2 mL, respectively, results in a concentration of 350 mg\/mL.<\/li><li>Do not use the 250 mg vial for a 350 mg\/mL concentration because withdrawal of the entire contents of the vial may not be possible.<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>do not administer simultaneously with calcium-containing solutions (eg, Ringer or Hartmann solution), products, or continuous calcium-containing infusions (eg, parenteral nutrition) in the same IV line or Y-site due to risk of precipitate formation<\/li><li>(neonates) use is contraindicated if calcium-containing IV solutions or continuous calcium-containing IV solutions are required or expected to be required due to risk of precipitate formation<\/li><li>(in non-neonates) calcium-containing solutions may be sequentially administered after thorough flushing of IV line with compatible solution between infusions<\/li><li>appropriate diluents are Sterile Water for Injection, NS, D5W, and D10W<\/li><li>reconstitution of the 250-mg, 500-mg, 1-g, and 2-g vials with 2.4 mL, 4.8 mL, 9.6 mL, and 19.2 mL, respectively, of appropriate diluent results in a concentration of 100 mg\/mL<\/li><li>after reconstitution, may further dilute to desired concentration with an appropriate IV diluent for infusion<\/li><li>infuse over 30 minutes; concentrations between 10 mg\/mL and 40 mg\/mL are preferred, but lower concentrations may be used<\/li><\/ul><\/li><\/ul>"},"10":{"id":"111736-s-10","title":"Monitoring","mono":"<ul><li>fever<\/li><li>symptomatic improvement<\/li><li>CBC<\/li><li>hepatic\/renal function<\/li><li>previous hypersensitivity to other beta-lactam antibiotics<\/li><li>signs of antibiotic-associated diarrhea, other superinfections<\/li><\/ul>"},"11":{"id":"111736-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Injection Powder for Solution: 1 GM, 2 GM, 10 GM, 250 MG, 500 MG<\/li><li>Intravenous Powder for Solution: 10 GM<\/li><li>Intravenous Solution: 1 GM\/50 ML, 2 GM\/50 ML<\/li><\/ul><\/li><li><b>Amerinet Choice cefTRIAXone<\/b><br\/>Injection Powder for Solution: 1 GM, 2 GM<br\/><\/li><li><b>Novaplus cefTRIAXone<\/b><br\/><ul><li>Injection Powder for Solution: 2 GM, 250 MG<\/li><li>Intravenous Powder for Solution: 10 GM<\/li><\/ul><\/li><li><b>PremierPro Rx cefTRIAXone<\/b><br\/>Injection Powder for Solution: 1 GM, 2 GM, 500 MG<br\/><\/li><li><b>Rocephin<\/b><br\/>Injection Powder for Solution: 1 GM, 250 MG, 500 MG<br\/><\/li><\/ul>"},"12":{"id":"111736-s-12","title":"Toxicology","sub":[{"id":"111736-s-12-31","title":"Clinical Effects","mono":"<b>CEPHALOSPORINS<\/b><br\/>OVERDOSE: Acute ingestion of large doses of cephalosporins may result in nausea, vomiting, diarrhea, and abdominal pain. Seizures have developed after parenteral overdose. ADVERSE EFFECTS: COMMON: Hypersensitivity reactions, including anaphylaxis, may commonly occur with therapy; oral exposures are less likely to cause severe allergic reactions than parenteral exposures. Seizures have also been reported following therapeutic administration. Prolonged prothrombin times, thrombocytopenia, and coagulopathies associated with a qualitative platelet defect and aggregation abnormalities have been reported following IV cephalosporin therapy. Pseudocholelithiasis may follow intravenous administration of ceftriaxone. Several cases of fatal hemolytic reactions following intravenous ceftriaxone therapy have been reported in children with serious hematologic abnormalities.<br\/>"},{"id":"111736-s-12-32","title":"Treatment","mono":"<b>CEPHALOSPORINS <\/b><br\/><ul><li>Decontamination: Generally not indicated in patients with no underlying health problems. Activated charcoal may be necessary for patients with underlying renal insufficiency.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Monitoring of patient: Monitor renal function, electrolytes, CBC including platelets.<\/li><li>Anaphylaxis: Mild to moderate allergic reactions may be treated with antihistamines with or without inhaled beta adrenergic agonists, corticosteroids or epinephrine. Diphenhydramine: ADULTS: 50 mg orally, IV, or IM initially, then 25 to 50 mg orally every 4 to 6 hours for 24 to 72 hours. CHILDREN: 1.25 mg\/kg orally, IV, or IM initially, then 5 mg\/kg\/day orally in 4 divided doses for 24 to 72 hours. Treatment of severe anaphylaxis also includes oxygen supplementation, aggressive airway management, epinephrine, ECG monitoring, and IV fluids.<\/li><li>Seizure: IV benzodiazepines, barbiturates<\/li><li>Blood coagulation disorder: Vitamin K, fresh frozen plasma<\/li><li>Intrathecal injection: Treat seizures with anticonvulsants (benzodiazepines, propofol, phenobarbital); endotracheal intubation and mechanical ventilation as needed. Keep the patient upright if possible. Immediately drain at least 20 mL CSF; drainage of up to 70 mL has been tolerated in adults. Follow with CSF exchange (remove serial 20 mL aliquots CSF and replace with equivalent volumes of warmed, preservative free normal saline or lactated ringers). For large overdoses, consult a neurosurgeon for placement of a ventricular catheter and begin ventriculolumbar perfusion (infuse warmed preservative free normal saline or lactated ringers through ventricular catheter, drain fluid from lumbar catheter; typical volumes 80 to 150 mL\/hr). Dexamethasone 4 mg intravenously every 6 hours to prevent arachnoiditis.<\/li><\/ul>"},{"id":"111736-s-12-33","title":"Range of Toxicity","mono":"<b>CEPHALOSPORINS<\/b><br\/>TOXICITY: Serious toxicity is unlikely following large oral doses of cephalosporins. Crystalluria and hematuria has been described in a 3-year-old boy who ingested 104 mg\/kg of cephalexin. THERAPEUTIC DOSE: Varies with agent. CEPHALEXIN: CHILDREN:  25 to 100 milligrams\/kilogram\/24 hours orally, up to a maximum of 4 grams\/day, divided every 6 hours. <br\/>"}]},"13":{"id":"111736-s-13","title":"Clinical Teaching","mono":"Advise patient to report severe diarrhea and consult healthcare professional prior to taking anti-diarrhea medicine. Other superinfection signs\/symptoms should be reported as well.<br\/>"}}}